--- title: Certis Oncology White Papers (2) description: Certis Oncology's White Papers. Keep up with the latest developments in O-PDX and innovative Cancer Research for Patients, Oncologists and Drug Development. (2) --- [![CERTIS](https://whitepapers.certisoncology.com/hubfs/certis-lockup-horz-color.svg "CERTIS")](https://www.certisoncology.com/) - [Home](https://www.certisoncology.com/) - Drug Developers - [CertisAI™️](https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence/) - [Cancer Models](https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies/) - [Custom Models](https://www.certisoncology.com/for-drug-developers/custom-model-development/) - [In Vitro/Ex Vivo](https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology/) - [In Vivo](https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology/) - [Imaging/Endpoints](https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis/) - [Immuno-Oncology](https://www.certisoncology.com/for-drug-developers/immuno-oncology/) - Oncologists - [Order YourPDX®](https://www.certisoncology.com/for-oncologists/order-yourpdx/) - [Clinical Research](https://www.certisoncology.com/for-oncologists/clinical-research/) - [Patient Education](https://www.certisoncology.com/for-oncologists/patient-education/) - About - [Mission, Vision & Values](https://www.certisoncology.com/about-us/mission-vision-values/) - [Team](https://www.certisoncology.com/about-us/our-team/) - [Our Story](https://www.certisoncology.com/about-us/our-story/) - [Careers](https://www.certisoncology.com/about-us/careers/) - [Company News](https://www.certisoncology.com/about-us/news/) - [Contact Us](https://www.certisoncology.com/contact-us/) - Resource Library - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts/) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results/) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research/) - [Media](https://www.certisoncology.com/resources/media/) - [White Papers](https://news.certisoncology.com/) - [Contact](https://www.certisoncology.com/contact-us/) [Database Login](https://oncointel.certisoncology.com) ![CTA\_KRAS-CertiScreen-824x424-1-720x424](https://whitepapers.certisoncology.com/hs-fs/hubfs/CTA_KRAS-CertiScreen-824x424-1-720x424.jpg?width=720&name=CTA_KRAS-CertiScreen-824x424-1-720x424.jpg "CTA_KRAS-CertiScreen-824x424-1-720x424") ### VALIDATE YOUR KRAS-TARGETING STRATEGY Combining Predictive AI + Advanced Cancer Models to Help Direct Oncology Drug Development and Clinic Research Studies. [LEARN MORE](https://www.certisoncology.com/kras-targeted-oncology-drug-development/) - [Home](https://www.certisoncology.com/) - Drug Developers - Drug Developers - [CertisAI™️](https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence/) - [Cancer Models](https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies/) - [Custom Models](https://www.certisoncology.com/for-drug-developers/custom-model-development/) - [In Vitro/Ex Vivo](https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology/) - [In Vivo](https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology/) - [Imaging/Endpoints](https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis/) - [Immuno-Oncology](https://www.certisoncology.com/for-drug-developers/immuno-oncology/) - Oncologists - Oncologists - [Order YourPDX®](https://www.certisoncology.com/for-oncologists/order-yourpdx/) - [Clinical Research](https://www.certisoncology.com/for-oncologists/clinical-research/) - [Patient Education](https://www.certisoncology.com/for-oncologists/patient-education/) - About - About - [Mission, Vision & Values](https://www.certisoncology.com/about-us/mission-vision-values/) - [Team](https://www.certisoncology.com/about-us/our-team/) - [Our Story](https://www.certisoncology.com/about-us/our-story/) - [Careers](https://www.certisoncology.com/about-us/careers/) - [Company News](https://www.certisoncology.com/about-us/news/) - [Contact Us](https://www.certisoncology.com/contact-us/) - Resource Library - Resource Library - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts/) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results/) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research/) - [Media](https://www.certisoncology.com/resources/media/) - [White Papers](https://news.certisoncology.com/) - [Contact](https://www.certisoncology.com/contact-us/) ![CTA\_KRAS-CertiScreen-824x424-1-720x424](https://whitepapers.certisoncology.com/hs-fs/hubfs/CTA_KRAS-CertiScreen-824x424-1-720x424.jpg?width=720&name=CTA_KRAS-CertiScreen-824x424-1-720x424.jpg "CTA_KRAS-CertiScreen-824x424-1-720x424") ### VALIDATE YOUR KRAS-TARGETING STRATEGY Combining Predictive AI + Advanced Cancer Models to Help Direct Oncology Drug Development and Clinic Research Studies. [LEARN MORE](https://www.certisoncology.com/kras-targeted-oncology-drug-development/) ![hero-headline\_certainty-saves-lives](https://whitepapers.certisoncology.com/hubfs/hero-headline_certainty-saves-lives.svg) - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts/) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results/) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research/) - [Media](https://www.certisoncology.com/resources/media/) - [White Papers](https://news.certisoncology.com) ### Mimicking the "Seed and Soil:" The State of PDX Models of Breast Cancer Metastases October 27, 2022 Why do the quaintest analogies stick to biology’s most morbid phenomena? Look no further than English surgeon Stephen Paget’s “seed and soil” model for breast cancer metastasis for a prototypical example. In his 1889 publication in the Lancet, Paget... [Read More](https://whitepapers.certisoncology.com/mimicking-the-seed-and-soil-the-state-of-pdx-models-of-breast-cancer-metastases) ### New Certis Whitepaper: Bringing Certainty to PDX Model Characterization September 28, 2022 EXECUTIVE SUMMARY Patient-derived xenograft (PDX) models are indispensable for translational cancer research. However, public and private PDX tumor banks may lack standard quality controls, which may lead to genomic and transcriptomic... [Read More](https://whitepapers.certisoncology.com/new-certis-whitepaper-bringing-certainty-to-pdx-model-characterization) ### Improving Drug Development and Glioblastoma Xenograft Models September 19, 2022 Overcoming Glioblastoma Multiforme (GBM) Drug Development Challenges With Glioblastoma Xenograft Models Primary brain tumors are highly heterogeneous tumors that cause significant morbidity and mortality. An estimated 700,000 Americans are living... [Read More](https://whitepapers.certisoncology.com/glioblastoma-xenograft-models) ### Developing Clinically Relevant Metastatic Colorectal Cancer Models: From Carcinogens to Xenografts March 23, 2022 Colorectal cancer (CRC) is common and deadly, making up an estimated 7.9% of all new cancer cases and 8.7% of all cancer deaths in the U.S. last year.1 Cancer mortality often results from metastasis, which for colorectal cancer, happens frequently; ... [Read More](https://whitepapers.certisoncology.com/developing-clinically-relevant-metastatic-colorectal-cancer-models-from-carcinogins-to-xenographs) ### How to Identify High-Quality Hits Early On: Your Guide to Ensuring Reproducible In Vitro Oncology Studies November 23, 2021 In the past several decades, oncology drug development has had some major successes, from the approval of game-changing therapeutics such as rituximab and trastuzumab in the late-90s to the first tumor-agnostic approval for pembrolizumab in 2017.1... [Read More](https://whitepapers.certisoncology.com/how-to-identify-high-quality-hits-early-on-your-guide-to-ensuring-reproducible-in-vitro-oncology-studies) ### Sarcomas vs. pharmaceutical science June 02, 2021 THE RIGHT TUMOR MODELS BRING GREATER CERTAINTY TO DRUG CANDIDATE SELECTION [Read More](https://whitepapers.certisoncology.com/sarcomas-vs.-pharmaceutical-science) ### Making precision oncology more personal May 10, 2021 FROM GENETIC TESTING FOR CANCER TO FUNCTIONAL, PATIENT-DERIVED MODELS Genetic testing for cancer has rapidly become an important and routine part of oncology treatment. It’s driven the rise of precision oncology, where clinicians seek to match the... [Read More](https://whitepapers.certisoncology.com/from-genetic-testing-for-cancer-to-functional-precision-oncology) ### Predicting Therapeutic Response & Drug Resistance with O-PDX April 27, 2021 AACR 2021 Poster #2929: Predicting Patient’s Therapeutic Response and Acquired Drug Resistance with Orthotopic Patient-Derived Xenografts (O-PDX) Patient-derived xenografts (PDX) are a commonly used in vivo model that can provide clinically... [Read More](https://whitepapers.certisoncology.com/aacr-2021-poster) ### The Subcutaneous Xenograft vs Orthotopic Xenograft Debate April 12, 2021 Subcutaneous vs Orthotopic Xenografts: Identifying Clinically Relevant Models for Making More Accurate, Personalized Cancer Treatment Decisions In our last blog, we explored some of the current gaps in personalized medicine and how patient-derived... [Read More](https://whitepapers.certisoncology.com/subcutaneous-vs-orthotopic-xenografts) ### Making More Accurate, Personalized Cancer Treatment Decisions With Clinically Relevant PDX Models March 16, 2021 In the past few decades, researchers and clinicians have gained a deep understanding of the biology behind tumor growth and metastasis and the clinical course for many different types of cancers. Despite these advancements, cancers are still treated... [Read More](https://whitepapers.certisoncology.com/personalized-cancer-treatment-decisions-with-better-pdx-models) [Prev](https://whitepapers.certisoncology.com/page/1) [1](https://whitepapers.certisoncology.com/page/1) [2](https://whitepapers.certisoncology.com/page/2) [3](https://whitepapers.certisoncology.com/page/3) [Next](https://whitepapers.certisoncology.com/page/3) ![Certis](https://whitepapers.certisoncology.com/hubfs/certis-logo-lockup-white.svg "Certis") 5626 Oberlin Drive, Suite 110 San Diego, CA 92121 Drug Development: 858-988-1033 Patients & Oncologists: 858-228-4110 Main: 858-952-1820 - #### Drug Developers - [CertisAI™](https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence) - [Cancer Models](https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies) - [Custom Model Development](https://www.certisoncology.com/for-drug-developers/custom-model-development) - [In Vitro/Ex Vivo Pharmacology](https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology) - [In Vivo Pharmacology](https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology) - [Imaging/Endpoint Analysis](https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis) - [Immuno-Oncology](https://www.certisoncology.com/for-drug-developers/immuno-oncology/) - #### Oncologists - [Order YourPDX®](https://www.certisoncology.com/for-oncologists/order-yourpdx/) - [Clinical Research](https://www.certisoncology.com/for-oncologists/clinical-research/) - [Patient Education](https://www.certisoncology.com/for-oncologists/patient-education/) - #### Resource Library - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research) - [Media](https://www.certisoncology.com/resources/media) - [White Papers](https://news.certisoncology.com/) - #### About - [Mission, Vision & Values](https://www.certisoncology.com/about-us/mission-vision-values) - [Team](https://www.certisoncology.com/about-us/our-team) - [Our Story](https://www.certisoncology.com/about-us/our-story) - [Careers](https://www.certisoncology.com/about-us/careers) - [Company News](https://www.certisoncology.com/about-us/news/) - [Contact Us](https://www.certisoncology.com/contact-us) - [Login](https://oncointel.certisoncology.com) - [Privacy Policy](https://www.certisoncology.com/privacy-policy) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--facebook.svg)](https://www.facebook.com/CertisOncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--linkedin.svg)](https://www.linkedin.com/company/certis-oncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--twitter.svg)](https://twitter.com/CertisOncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--instagram.svg)](https://www.instagram.com/certis_oncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--youtube.svg)](https://www.youtube.com/channel/UCeX4_jh3RlNKxQxZ89_utjg) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--blog.svg)](https://blog.certisoncology.com/) ![certis-footer-mouse](https://whitepapers.certisoncology.com/hubfs/certis-footer-mouse.svg "certis-footer-mouse") --- ©2024 Certis Oncology Solutions. All rights reserved. Testimonials appearing on this site reflect real-life experiences of those who have used our services. To protect their privacy, photos feature models.